Root Financial Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Root Financial Partners’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1	Buy	+1	New	+$1	﹤0.01%	3826

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return

Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Root Financial Partners's LCTX Position: Q3 2026 in Review

Root Financial Partners opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #3826 among its holdings.

73 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

Root Financial Partners held 1 share of Lineage Cell Therapeutics worth $1 as of Q3 2026.
Lineage Cell Therapeutics was a new Root Financial Partners position in Q3 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3826 holding.
73 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.